Shield Therapeutics's total assets for Q2 2026 were £53.92M, a decrease of -17.34% from the previous quarter. DE:1JS total liabilities were £71.04M for the fiscal quarter, a -11.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.